Due diligence challenges in life sciences M&A: the need to focus on regulatory compliance, product liability and data integrity

Merger and acquisition (M&A) transactions in the healthcare and life sciences sectors in France can involve the acquisition of companies that market health products, such as medical device manufacturers, or the purchase of equity interests in clinical groups and professional healthcare entities (La société d'exercice libéral à responsabilité limitée or SELARLS). These operations attract significant investor interest, but also demand a high degree of legal and regulatory scrutiny.

‍

Because healthcare entities operate under distinct and often overlapping national and European regulatory schemes, legal practitioners must navigate a complex web of statutory and compliance obligations to structure secure and compliant acquisitions.

‍

Three key elements must be taken into account during the due diligence process in order to understand the risks posed by an acquisition transaction in the healthcare and life sciences sector, which are:

- Regulatory compliance

- Product liability

- Data integrity

‍

Update with our partner Mathieu Gauthier for the IBA.